-
Imatinib results in significant and durable responses for CML. The safety of discontinuation has not been rigorously tested. In a prospective study, imatinib was discontinued among CML patients in a complete molecular remission (CMR) for 2 years or more. Among 69 patients with at least one year of follow-up, 61% relapsed by molecular analysis, almost all by 6 months. After imatinib reintroduction, all 42 relapsing patients responded, of which 26 (62%) entered CMR again. High Sokal score at baseline, female sex, and shorter period of CMR predicted for relapse on imatinib discontinuation. Around 40% of patients with CML in prolonged CMR on imatinib do not relapse at least one year after stopping the drug.
-
Castleman's disease (CD), angiofollicular lymph- node hyperplasia, was initially described a half century ago in asymptomatic patients with a mediastinal mass.
-
Consumption of alcohol among women who had received primary treatment for breast cancer was not associated with increased risk of breast cancer recurrence. In fact, for non-obese patients, alcohol intake was associated with other favorable prognostic factors and improved overall survival.
-
-
Tiotropium for uncontrolled asthma, sibutramine pulled from market, incidence and mortality data from WHI, FDA Actions.
-
-
Dual anti-platelet therapy with aspirin and a thienopyridine, such as clopidogrel, is recommended after ST elevation myocardial infarction (MI).
-
Implantable cardiac rhythm devices are being used in an increasing number of patients and, in addition, patients who receive them are living longer.
-
Increases in cardiac volume in the non-pregnant state increase BNP, but little is known about pregnancy and BNP levels.
-
Tiotropium for uncontrolled asthma, sibutramine pulled from market, incidence and mortality data from WHI, FDA Actions.
